The reduction in price target by Stifel suggests a less optimistic outlook on Sage Therapeutics' stock value, which could lead to a negative short-term impact on the stock price. The Hold rating indicates that the analyst does not see significant upside or downside in the near term, but the lowered price target may influence investor sentiment negatively.